Expression and Prognostic Correlation Analysis of NUTF2 in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients
-
摘要:
目的 探究核转运因子2(NUTF2)在头颈部鳞状细胞癌(HNSCC)患者中的表达,并分析其与预后的关系。 方法 选取2016年3月至2017年2月邯郸市中心医院HNSCC患者269例,以免疫组织化学染色法检测NUTF2表达水平,比较肿瘤组织与癌旁组织、不同肿瘤分期患者NUTF2表达水平。分析NUTF2表达水平与肿瘤分期的相关性及HNSCC患者生存结局的影响因素。比较不同NUTF2表达水平HNSCC患者的生存情况。通过体外实验观察NUTF2表达水平变化对HNSCC细胞增殖和凋亡的影响。 结果 HNSCC患者肿瘤组织NUTF2表达水平高于癌旁组织(P < 0.05);HNSCC患者NUTF2表达水平与肿瘤分期呈正相关(P < 0.05);NUTF2表达水平(HR = 3.478,95%CI为1.752~6.906)是HNSCC患者生存结局的影响因素(P < 0.05);NUTF2高表达HNSCC患者生存率低于NUTF2低表达患者(HR = 0.486,95%CI为0.298~0.793,χ2 = 8.345,P = 0.004)。NUTF2表达敲低抑制HNSCC细胞增殖,促进细胞凋亡。 结论 NUTF2表达水平在HNSCC患者肿瘤组织内异常升高,对患者生存结局存在直接影响,NUTF2高表达提示患者预后较差。 Abstract:Objective To explore the expression of nuclear transport factor 2 (NUTF2) in patients with head and neck squamous cell carcinoma (HNSCC) and analyze its relationship with prognosis. Methods 269 HNSCC patients from Handan Central Hospital between March 2016 and February 2017 were selected. Immunohistochemical staining was used to detect NUTF2 expression levels, comparing tumor tissues with adjacent tissues and NUTF2 expression across different tumor stages. The correlation between NUTF2 expression levels and tumor staging, as well as factors influencing HNSCC patient survival outcomes, were analyzed. Survival situations of HNSCC patients with different NUTF2 expression levels were compared. In vitro experiments were conducted to observe the effects of NUTF2 expression level changes on HNSCC cell proliferation and apoptosis. Results NUTF2 expression levels in HNSCC tumor tissues were higher than in adjacent tissues (P < 0.05); NUTF2 expression levels were positively correlated with tumor staging (P < 0.05). NUTF2 expression level (HR = 3.478, 95%CI 1.752~6.906) was a factor influencing HNSCC patient survival outcomes(P < 0.05); HNSCC patients with high NUTF2 expression had lower survival rates compared to those with low NUTF2 expression (HR = 0.486, 95%CI 0.298~0.793, χ2 = 8.345, P = 0.004). Knockdown of NUTF2 expression inhibited HNSCC cell proliferation and promoted cell apoptosis. Conclusion NUTF2 expression levels are abnormally elevated in HNSCC tumor tissues, directly affecting patient survival outcomes, with high NUTF2 expression indicating a poorer prognosis. -
表 1 HNSCC患者不同组织中NUTF2表达水平比较[($\bar x \pm s $),分]
Table 1. Comparison of NUTF2 expression levels in different tissues of HNSCC patients [($\bar x \pm s $),score]
组织类型 n NUTF2表达水平 t P 肿瘤组织 269 6.11±1.91 46.037 <0.001* 癌旁组织(≥2 cm) 269 0.71±0.23 0.825# 0.872 正常黏膜对照 20 0.69±0.21 0.825# 0.872 #为癌旁组织与正常黏膜对照的t检验值;癌旁组织取材标准:距肿瘤边缘≥2 cm且无癌前病变;*P < 0.05。 表 2 不同肿瘤分期HNSCC患者NUTF2表达水平比较[($\bar x \pm s $),分]
Table 2. Comparison of NUTF2 expression levels in HNSCC patients with different tumor staging [($\bar x \pm s $),score]
肿瘤分期 n NUTF2表达水平 F P Ⅰ期(T1N0M0) 62 4.86±1.28 21.576 <0.001* Ⅱ期(T2N0M0) 66 5.54±1.54 18.324 <0.001* Ⅲ期(T3N0M0或T1-3N1M0) 61 6.65±1.49 15.789 <0.001* Ⅳ期(T4或N2) 80 7.14±1.61 12.456 <0.001* *P < 0.05。 表 3 不同生存结局HNSCC患者一般资料比较[n(%)]
Table 3. Comparison of general information of HNSCC patients with different survival outcomes [n(%)]
一般资料 类别 生存(n=183) 死亡(n=74) χ2/Z P 性别 男 118(64.48) 49(66.22) 0.070 0.792 女 65(35.52) 25(33.78) 年龄(岁) <60 111(60.66) 44(59.46) 0.032 0.859 ≥60 72(39.34) 30(40.54) 合并症 糖尿病 22(12.02) 14(18.92) 2.081 0.149 高血压 38(20.77) 20(27.03) 1.182 0.277 肿瘤分期 Ⅰ期 61(33.33) 0(0.00) 9.039 <0.001* Ⅱ期 54(29.51) 4(5.41) Ⅲ期 41(22.40) 17(22.97) Ⅳ期 27(14.75) 53(71.62) 肿瘤部位 口咽 49(26.78) 14(18.92) 3.673 0.299 口腔 51(27.87) 29(39.19) 鼻咽 63(34.43) 23(31.08) 其他 20(10.93) 8(10.81) 治疗方式 根治性手术 82(44.81) 23(31.08) 4.192 0.123 根治性手术+化疗 60(32.79) 32(43.24) 放疗+化疗 41(22.40) 19(25.68) 分化程度 低分化 24(13.11) 36(48.65) 6.054 <0.001* 中分化 68(37.16) 27(36.49) 高分化 91(49.73) 11(14.86) 吸烟史 有 59(32.24) 35(47.30) 5.150 0.023* 无 124(67.76) 39(52.70) HPV感染 阴性 109(59.56) 33(44.59) 4.775 0.029* 阳性 74(40.44) 41(55.41) NUTF2表达 高表达 91(49.73) 48(64.86) 4.863 0.027* 低表达 92(50.27) 26(35.14) 淋巴结转移 有 131(71.58) 65(87.84) 7.690 0.006* 无 52(28.42) 9(12.16) 肿瘤直径(cm) <2 46(25.14) 21(28.38) 3.855 0.146 2~4 83(45.36) 24(32.43) >4 54(29.51) 29(39.19) *P < 0.05。 表 4 HNSCC患者生存结局影响因素分析赋值方案
Table 4. Analysis of factors influencing the prognosis of HNSCC patients with assignment schemes
序号 项目 变量名 赋值方案 1 生存结局 因变量 生存=0、死亡=1 2 分化程度 自变量 高分化=1、中分化=2、低分化=3 3 吸烟史 自变量 无=0、有=1 4 HPV感染 自变量 阴性=0、阳性=1 5 NUTF2表达水平 自变量 低表达=1、高表达=2 表 5 移除肿瘤分期、淋巴结转移后HNSCC患者生存结局的影响因素分析
Table 5. Factors influencing survival outcomes in HNSCC patients after removal of tumor stage,lymph node metastasis
项目 β SE Waldχ2 HR P 95%CI 分化程度 0.403 0.429 0.883 1.496 0.516 0.837~2.675 吸烟史 0.175 0.386 0.206 1.191 0.703 0.725~1.958 HPV感染 0.519 0.452 1.317 1.680 0.435 0.914~3.088 NUTF2 1.247 0.396 9.909 3.478 <0.001* 1.752~6.906 *P < 0.05。 表 6 移除NUTF2表达水平后HNSCC患者生存结局的影响因素分析
Table 6. Factors influencing survival outcomes in HNSCC patients after removal of NUTF2 expression level
项目 β SE Waldχ2 HR P 95%CI 肿瘤分期 1.056 0.315 11.234 2.876 <0.001* 1.802~4.589 淋巴结转移 0.795 0.281 8.012 2.214 0.001* 1.376~3.562 分化程度 0.605 0.238 6.452 1.832 0.011* 1.152~2.914 吸烟史 0.218 0.192 1.289 1.243 0.264 0.847~1.824 HPV感染情况 0.145 0.195 0.553 1.156 0.453 0.792~1.688 *P < 0.05。 表 7 不同NUTF2表达水平HNSCC患者的生存时间比较
Table 7. Comparison of survival time in HNSCC patients with different NUTF2 expression level
组别 n 中位生存时间(月) 95%CI 1年生存率(%) 3年生存率(%) 5年生存率(%) NUTF2高表达 139 38.2 32.5~43.9 89.2 64.7 41.0 NUTF2低表达 118 56.8 49.5~64.1 98.3 82.1 73.5 表 8 细胞增殖实验结果($\bar x \pm s $)
Table 8. Results of cell proliferation experiment ($\bar x \pm s $)
细胞系 处理组 OD F P CAL27 si-NC 2.35±0.21 28.724 <0.001* si-NUTF2-1 1.28±0.15 si-NUTF2-2 1.31±0.17 SCC-9 si-NC 2.41±0.19 32.562 <0.001* si-NUTF2-1 1.16±0.12 FaDu OE-Vector 2.29±0.23 25.245 <0.001* OE-NUTF2 3.07±0.31 *P < 0.05。 表 9 细胞凋亡流式检测结果($\bar x \pm s $)
Table 9. Flow cytometry results of apoptosis assay ($\bar x \pm s $)
细胞系 处理组 早期凋亡
率(%)晚期凋亡
率(%)总凋亡率
(%)CAL27 si-NC 5.2±1.1 3.8±0.9 9.0±1.5 si-NUTF2-1 12.7±2.3 16.4±3.1 29.1±4.2 t 5.095 6.761 7.902 P 0.007* 0.003* 0.001* SCC-9 OE-Vector 4.8±1.0 4.1±1.2 8.9±1.8 OE-NUTF2 3.1±0.7 2.5±0.6 5.6±1.1 t 4.712 5.066 6.104 P 0.013* 0.008* 0.005* *P < 0.05。 -
[1] Douglas C M,Ingarfield K,McMahon A D,et al. Presenting symptoms and long-term survival in head and neck cancer[J]. Clin Otolaryngol,2018,43(3):795-804. doi: 10.1111/coa.13053 [2] Große-Thie C,Maletzki C,Junghanss C,et al. Long-term survivor of metastatic squamous-cell head and neck carcinoma with occult primary after cetuximab-based chemotherapy: A case report[J]. World J Clin Cases,2021,9(24):7092-7098. doi: 10.12998/wjcc.v9.i24.7092 [3] Stratigos A,Garbe C,Lebbe C,et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline[J]. Eur J Cancer,2015,51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110 [4] 梁登桓,刘家琦,李东慧,等. 头颈部鳞状细胞癌中USP10的表达及其预后价值[J]. 口腔医学研究,2024,40(5):417-421. [5] Pfister D G,Spencer S,Adelstein D,et al. Head and neck cancers,version 2.2020,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2020,18(7):873-898. doi: 10.6004/jnccn.2020.0031 [6] McDermott J D,Bowles D W. Epidemiology of head and neck squamous cell carcinomas: Impact on staging and prevention strategies[J]. Curr Treat Options Oncol,2019,20(5):43. doi: 10.1007/s11864-019-0650-5 [7] Vuković L D,Chen P,Mishra S,et al. Nuclear transport factor 2 (NTF2) suppresses WM983B metastatic melanoma by modifying cell migration,metastasis,and gene expression[J]. Sci Rep,2021,11(1):23586. doi: 10.1038/s41598-021-02803-0 [8] Li T,Li S,Liang C,et al. Chemical shift assignments of RHE_RS02845,a NTF2-like domain-containing protein from Rhizobium etli[J]. Biomol NMR Assign,2018,12(2):249-252. doi: 10.1007/s12104-018-9817-4 [9] 高晓雨,杨艳平,仝妍,等. 核转运蛋白2在头颈部鳞状细胞癌中的表达及其意义[J]. 广西医科大学学报,2020,37(2):177-181. [10] Li X,Deng S J,Zhu S,et al. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway[J]. Oncotarget,2016,7(5):6000-6014. doi: 10.18632/oncotarget.6830 [11] 李鹏,常玉喜,闫相涛,等. 血管内皮生长因子和程序性死亡分子配体1在肺鳞癌组织中的表达及对预后的影响[J]. 临床肿瘤学杂志,2019,24(3):212-217. doi: 10.3969/j.issn.1009-0460.2019.03.004 [12] Butkiewicz D,Gdowicz-Kłosok A,Krześniak M,et al. Association of genetic variants in ANGPT/TEK and VEGF/VEGFR with progression and survival in head and neck squamous cell carcinoma treated with radiotherapy or radiochemotherapy[J]. Cancers (Basel),2020,12(6):1506. doi: 10.3390/cancers12061506 [13] 孙青,吕丹雨,秦雪梅,等. 喉鳞癌中DNA结合/分化抑制蛋白-2和血管内皮生长因子-C表达及临床意义[J]. 陕西医学杂志,2019,48(1):74-76. doi: 10.3969/j.issn.1000-7377.2019.01.023 [14] 杨阳,李校天,张九娜,等. 血管内皮生长因子C和皮层肌动蛋白在食管鳞癌细胞中的表达及其临床意义[J]. 医学研究生学报,2019,32(5):501-505. [15] Liu J F,Deng W W,Chen L,et al. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer[J]. Mol Carcinog,2018,57(3):429-439. doi: 10.1002/mc.22767 [16] 葛乔枫,张龙,孙晓娟,等. 敲低核转运蛋白对人骨肉瘤细胞增殖和血管生成的体内影响[J]. 第三军医大学学报,2019,41(14):1308-1313. [17] Wang Y,Fu D,Chen Y,et al. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas[J]. Cell Death Dis,2018,9(5):501. doi: 10.1038/s41419-018-0504-2 [18] 鲁昱晟,杨文艺,马海龙,等. Ras相关结构域家族成员5对头颈鳞癌细胞迁移和侵袭能力的影响[J]. 上海交通大学学报(医学版),2021,41(6):717-723. doi: 10.3969/j.issn.1674-8115.2021.06.003 [19] Wu J,Du W,Wang X,et al. Ras-related protein Rap2c promotes the migration and invasion of human osteosarcoma cells[J]. Oncol Lett,2018,15(4):5352-5358. [20] Zhang R,Gao Y. Identification of NUTF2 as a candidate diagnostic and prognostic biomarker associated with immune infiltration in head and neck squamous cell carcinoma[J]. Onco Targets Ther,2021,14:5455-5467. doi: 10.2147/OTT.S337469 [21] Li Y,Huang Y,Ren S,et al. A pan-cancer analysis of the oncogenic role of nuclear transport factor 2 in human cancers[J]. Front Oncol,2022,12:829389. doi: 10.3389/fonc.2022.829389 [22] Li P,Wen X,Zhang X,et al. NUTF2 as a prognostic indicator and potential therapeutic target in head and neck squamous cell carcinoma[J]. Genet Test Mol Biomarkers,2022,26(12):553-563. doi: 10.1089/gtmb.2022.0102 [23] 张睿,吴梦鸽,刘芮吟,等. Hedgehog信号通路相关蛋白在头颈鳞状细胞癌中的表达及临床意义[J]. 现代肿瘤医学,2020,28(21):3693-3698. doi: 10.3969/j.issn.1672-4992.2020.21.010 [24] Chan LP,Liu C,Chiang F Y,et al. IL-8 promotes inflammatory mediators and stimulates activation of p38 MAPK/ERK-NF-κB pathway and reduction of JNK in HNSCC[J]. Oncotarget,2017,8(34):56375-56388. doi: 10.18632/oncotarget.16914 [25] 邵伟华,李晋,龚炜韬,等. Hippo-TAZ/YAP信号通路在头颈部鳞状细胞癌中的研究进展[J]. 口腔医学,2020,40(1):71-77. -
下载: